Compare JG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JG | EVAX |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | China | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 32.7M |
| IPO Year | 2018 | 2020 |
| Metric | JG | EVAX |
|---|---|---|
| Price | $5.69 | $3.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | 3.2K | ★ 29.4K |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $2.11 |
| 52 Week High | $12.74 | $12.15 |
| Indicator | JG | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 42.55 |
| Support Level | $5.00 | $3.35 |
| Resistance Level | $6.97 | $4.57 |
| Average True Range (ATR) | 0.35 | 0.27 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 13.84 | 27.19 |
Aurora Mobile Ltd provides stable, and accurate developer services for educational and medical products. It is focused on providing companies with stable and efficient push notification services. It provides a comprehensive suite of services to mobile app developers in mainland China. Through its developer services, it gains access to, aggregate, cleanse, structure and encrypt vast amounts of real-time and anonymous device-level mobile behavioral data. It offers data services such as iAPP which helps the investors to analyze opportunities in the sector, Anti-fraud helps to identify fraud risks, iAudience, iZone and other related services. The company operates in one segment and generates revenues from SAAS Businesses.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.